Another oral Gal-3 inhibitor, GB1211 was recently shown to substantially increase the binding of pembrolizumab and atezolizumab, in cancer cell lines overexpressing PD-1 and PD-L1 respectively (159), thus complementing the findings of Capalbo and colleagues (151). Here, LGALS3 is linked to cancer.